Living with nerve pain, numbness, tingling, or weakness changes daily life in ways that are hard to describe to someone who hasn’t experienced it. Whether it comes from diabetic neuropathy, an old injury, or age-related nerve degeneration, damaged nerves don’t always heal the way skin or muscle does — and conventional treatments often focus on managing symptoms rather than supporting the underlying nerve tissue.

Nerve Growth Factor (NGF) treatment is a regenerative medicine approach built around one of the body’s own signaling proteins — a molecule that plays a central role in how nerve cells grow, survive, and repair themselves. Interest in NGF-based therapy has grown across neurology, ophthalmology, and regenerative medicine, but it’s important to separate what is scientifically established from what is still being studied.

This guide explains what NGF is, how the nervous system naturally repairs itself, why nerve damage happens, what current research says about NGF therapy, and how it fits alongside other regenerative options such as stem cell and exosome therapy. The goal is a clear, balanced answer — not a promotional one.

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. NGF-based therapies vary widely in their level of clinical evidence and regulatory approval depending on the condition being treated. Always consult a qualified, licensed physician for a personal evaluation before pursuing any nerve treatment.

• Nerve Growth Factor (NGF) is a naturally occurring protein that supports the growth, survival, and maintenance of certain neurons.
• NGF-based treatment is an established, FDA-approved therapy for one specific condition — neurotrophic keratitis, a nerve-related eye disease — using a recombinant NGF eye drop.
• For most other applications, including peripheral neuropathy, spinal cord injury, and neurodegenerative disease, NGF therapy remains an active area of research rather than an approved, standardized treatment.
• NGF’s therapeutic promise is tempered by real delivery challenges: it has a short half-life and struggles to cross the blood-nerve and blood-brain barriers in adequate concentrations.
• NGF therapy is often discussed alongside other regenerative approaches, such as stem cell therapy and exosome therapy, which work through overlapping but distinct mechanisms.
• Anyone considering NGF-based treatment should ask specifically which condition is being treated, what evidence supports that use, and whether the specific product has any regulatory approval for that indication.

Definition: Nerve Growth Factor (NGF) is a small protein belonging to the neurotrophin family. It supports the growth, differentiation, and survival of specific neurons in both the peripheral and central nervous systems by binding to receptors on nerve cells, primarily TrkA and the p75 neurotrophin receptor.

NGF was first identified in the 1950s by Nobel laureate Rita Levi-Montalcini, whose research established the concept that nerve cells depend on signaling proteins from their environment to develop and survive. Since then, NGF has become one of the most studied molecules in neuroscience.

In a healthy nervous system, NGF is produced in small amounts by target tissues — including skin, the cornea, and certain internal organs — and taken up by nearby sensory and sympathetic neurons. This signaling helps neurons survive, maintain their connections, and, in some contexts, regenerate after injury. NGF levels and activity naturally decline with age, and disruptions to NGF signaling have been studied in connection with several neurological and ocular conditions.

Key takeaway: NGF is not a synthetic drug invented for therapy — it is a naturally occurring signaling protein that the body already uses to support nerve health, which is why researchers have worked to harness it therapeutically.

To understand why NGF therapy is being studied, it helps to understand how nerve repair works — and where it commonly falls short.

• Peripheral nerves (outside the brain and spinal cord) have some natural capacity to regenerate. After an injury, the portion of the axon beyond the injury site degenerates (a process called Wallerian degeneration), while Schwann cells help clear debris and form a pathway that the regenerating axon can potentially grow back along.
• Central nervous system tissue (the brain and spinal cord) has much more limited capacity for repair, due to an inhibitory environment, scar tissue formation, and a scarcity of the growth-supportive signals present in the peripheral nervous system.
• Neurotrophic support — signaling molecules like NGF, brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) — plays a role in whether a stressed or injured neuron survives, regenerates, or dies.
• Blood supply and inflammation both influence nerve healing; chronic inflammation and poor microcirculation can impair the regenerative process.

When natural neurotrophic signaling is insufficient — due to age, chronic disease, or the severity of injury — nerves may fail to regenerate effectively, leading to persistent numbness, pain, or weakness.

Nerve-related conditions have many possible underlying causes, including:

• Diabetes: Chronic high blood sugar damages small blood vessels supplying nerves and directly affects nerve fiber metabolism, leading to diabetic peripheral neuropathy.
• Trauma and compression: Physical injury, surgery, or chronic nerve compression (such as carpal tunnel syndrome) can damage axons directly.
• Aging: Nerve conduction velocity and neurotrophic signaling both tend to decline with age.
• Chemotherapy: Certain chemotherapy drugs are directly toxic to peripheral nerves, causing chemotherapy-induced peripheral neuropathy.
• Autoimmune and inflammatory conditions: Disorders such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy involve immune-mediated nerve damage.
• Nutritional deficiencies: Deficiencies in B vitamins, particularly B12, are a well-established cause of peripheral neuropathy.
• Vascular disease: Reduced blood flow limits the oxygen and nutrient delivery nerves need to function and repair.
• Neurodegenerative disease: Conditions such as Alzheimer’s disease and Parkinson’s disease involve progressive loss of specific neuron populations, some of which depend on neurotrophic signaling for survival.
• Ocular surface disease: Reduced corneal nerve density, sometimes from herpes infection, diabetes, or eye surgery, can cause neurotrophic keratitis, a condition in which the cornea loses sensation and its normal healing capacity.

Established, FDA-approved use:

• Neurotrophic keratitis: A recombinant human NGF eye drop (cenegermin) is approved by the FDA for this condition, in which reduced corneal nerve sensitivity impairs the eye’s ability to heal. This remains the clearest example of an NGF-based therapy with regulatory approval and controlled clinical trial support.

Active areas of research, not yet standard of care:

• Diabetic peripheral neuropathy: NGF’s role in sensory neuron survival has made it a research target, though clinical translation has faced delivery and dosing challenges.
• Peripheral nerve injury: Preclinical and some early clinical research has explored NGF delivered locally (for example, via nerve guidance conduits or injections) to support axon regeneration after trauma or surgery.
• Spinal cord injury: Neurotrophic factors including NGF are being studied as part of broader regenerative strategies, often in combination with cell-based therapies or biomaterial scaffolds.
• Alzheimer’s disease: Because NGF supports the survival of cholinergic neurons that are lost in Alzheimer’s disease, it has been investigated as a potential disease-modifying approach, including gene-therapy delivery methods, though clinical efficacy in patients remains unproven.
• Parkinson’s disease and other neurodegenerative conditions: Related neurotrophic factors are under investigation, with NGF representing one part of a broader research landscape.
• Diabetic corneal complications and dry eye disease: Beyond neurotrophic keratitis, topical NGF has been studied for its effects on corneal nerve health more broadly.

Key takeaway: NGF therapy exists on a spectrum — from one FDA-approved, evidence-backed application in ophthalmology, to multiple promising but still-investigational applications in neurology and nerve injury.

Proposed mechanisms include:

• Neuron survival signaling: NGF binding to TrkA receptors activates intracellular pathways associated with neuron survival and reduced cell death.
• Axon growth support: In peripheral nerve injury models, NGF signaling has been associated with enhanced axon outgrowth.
• Corneal nerve regeneration: In neurotrophic keratitis, topical NGF is thought to restore corneal nerve function, which in turn supports the cornea’s own healing and normal sensation.
• Synaptic maintenance: In the central nervous system, NGF is theorized to help maintain synaptic connections in vulnerable neuron populations, such as cholinergic neurons affected in Alzheimer’s disease.
• Modulation of the injury environment: NGF and related neurotrophic factors may influence inflammation and the surrounding tissue environment after nerve injury, though this is an area of ongoing study rather than settled science.

A key clinical challenge with NGF therapy — regardless of application — is delivery. NGF has a short biological half-life, does not easily cross the blood-brain or blood-nerve barrier in sufficient concentration, and can cause side effects such as pain at higher systemic doses. This is why successful clinical translation to date has focused on local, targeted delivery (such as eye drops for the cornea) rather than systemic administration.

Established clinical evidence: Randomized controlled trials support the use of recombinant NGF eye drops for neurotrophic keratitis, and this remains the primary FDA-approved indication for NGF-based therapy.

Peripheral nerve injury research: Laboratory and animal studies consistently show that NGF and related neurotrophic factors support axon regeneration and myelin repair after nerve injury. However, translating these findings into standardized, effective human treatments has been limited by delivery challenges, and NGF is not currently a standard-of-care treatment for peripheral nerve injury outside of specialized research settings.

Neurodegenerative disease research: Reviews of decades of NGF research for conditions like Alzheimer’s disease describe the therapeutic potential as real but still unproven in patients, citing ongoing challenges with delivering adequate, sustained NGF concentrations to the central nervous system safely. Approaches such as gene therapy delivery and combination strategies with neuromodulation techniques (for example, transcranial magnetic stimulation) are being explored to address these limitations.

Diabetic neuropathy research: Despite strong preclinical rationale, clinical trials of NGF for diabetic peripheral neuropathy have had mixed results, and it is not currently an approved or standard treatment for this condition.

Regulatory considerations: Regulatory approval for NGF-based products is condition-specific. A therapy being FDA-approved for one indication (such as neurotrophic keratitis) does not mean NGF is approved or validated for unrelated uses like general neuropathy, spinal cord injury, or cognitive decline. Patients should ask directly whether the specific NGF product and delivery method being offered has regulatory approval or clinical trial support for their particular condition.

Key takeaway: NGF is one of the best-studied molecules in neuroscience, with real clinical success in one specific, localized application. Its broader use for nerve injury and neurodegenerative disease remains an active, evolving research field rather than an established standard treatment.

Myth: NGF therapy is a universally approved treatment for all nerve damage. Fact: NGF-based treatment has clear regulatory approval for one specific condition, neurotrophic keratitis. Its use for other nerve conditions remains investigational.

Myth: Since NGF supports nerve growth in the lab, it will regenerate any damaged nerve in the body. Fact: Delivering NGF safely and effectively to injured nerves in adequate concentrations — especially in the brain and spinal cord — remains a major unresolved clinical challenge.

Myth: NGF therapy can reverse Alzheimer’s disease. Fact: While NGF’s role in supporting neurons affected by Alzheimer’s disease is scientifically interesting, clinical efficacy for treating or reversing the disease in patients remains unproven.

Myth: All “nerve growth factor” products offered by clinics are equivalent and standardized. Fact: NGF-based products vary significantly by formulation, delivery method, and regulatory status; patients should verify the specific evidence behind any product offered for their condition.

Regenerative medicine providers may consider NGF-related strategies alongside cell-based or exosome approaches when appropriate, since these therapies work through overlapping but distinct biological pathways. The right combination, if any, depends entirely on the specific condition, its severity, and the current evidence supporting each option for that condition.

• Detailed history: Your provider should review your specific condition, prior treatments, and relevant medical history.
• Diagnostic evaluation: Depending on the condition, this may include nerve conduction studies, corneal sensitivity testing, or imaging.
• Evidence discussion: A responsible provider will explain what level of evidence supports NGF therapy for your specific condition — distinguishing an FDA-approved use from an investigational one.
• Treatment planning: For approved applications, this follows established clinical protocols (such as topical eye drop dosing for neurotrophic keratitis). For investigational uses, treatment plans should be discussed transparently, including realistic expectations and any relevant research context.
• Follow-up monitoring: Ongoing assessment to track response and any side effects.

NGF-based treatment, in its FDA-approved form, is intended for:

• Patients diagnosed with neurotrophic keratitis by an ophthalmologist

NGF-related regenerative approaches may be discussed on an investigational basis for:

• Patients with peripheral nerve injury being evaluated in specialized or research settings
• Patients exploring regenerative options for neuropathy alongside their treating physician
• Individuals interested in the broader neurotrophic factor research landscape for neurodegenerative conditions, ideally through clinical trial participation

NGF therapy is not an appropriate substitute for:

• Standard medical management of underlying conditions such as diabetes
• Emergency or surgical treatment of acute nerve injuries
• Established, first-line treatments for neurodegenerative disease

A qualified specialist can help clarify which category your situation falls into and what the realistic evidence supports.

Reported risks and side effects associated with NGF therapy vary by formulation and route of administration, and may include:

• Eye discomfort or pain, commonly reported with topical NGF eye drops for neurotrophic keratitis
• Injection site reactions, when administered by injection in research settings
• Systemic pain, which has limited higher-dose systemic NGF administration in some studies
• Variable response, particularly for investigational, off-label, or research-stage applications
• Lack of standardization across non-approved NGF-based products and protocols offered outside of clinical trials

Because regulatory approval is condition-specific, using an NGF-based product for a condition outside its approved indication should be approached with particular caution, ideally within a clinical trial or under close specialist supervision.

Regardless of which regenerative treatment is used, several everyday factors influence nerve health and repair capacity:

• Blood sugar control: Tight glycemic control is one of the most important factors in preventing and slowing diabetic neuropathy progression.
• B-vitamin status: Adequate B12, B6, and folate support healthy nerve function; deficiencies should be corrected under medical guidance.
• Physical activity: Exercise supports circulation, which benefits nerve tissue oxygenation and nutrient delivery.
• Smoking cessation: Smoking impairs microcirculation, which can worsen nerve-related symptoms.
• Alcohol moderation: Excess alcohol intake is a recognized contributor to peripheral neuropathy.
• Sleep quality: Adequate sleep supports overall neurological health and pain regulation.
• Weight management: Maintaining a healthy weight reduces metabolic strain associated with several nerve conditions.
• Protecting against repetitive injury: Avoiding repetitive compression or trauma (such as prolonged nerve compression at the wrist or elbow) helps prevent further nerve damage.

Nerve Growth Factor therapy is one part of a broader regenerative medicine landscape. You may also find these related resources helpful:

• Explore stem cell therapy as a broader regenerative approach to tissue and nerve repair
• Learn more about exosome therapy and its cell-free regenerative mechanisms
• Read about exosome therapy for hair loss, another application of regenerative signaling therapy
• Explore aging and longevity treatments in regenerative medicine
• Learn about anti-aging regenerative therapies
• Discover skin rejuvenation treatments that use similar growth factor signaling principles

If you’re considering NGF-related treatment for a specific nerve condition, our regenerative medicine services overview outlines related therapies, and you can reach out through our consultation page to discuss your case with a specialist.

Nerve Growth Factor is one of the most thoroughly studied molecules in neuroscience, with a clear, evidence-backed clinical success story in neurotrophic keratitis and a much broader, still-developing research story in peripheral nerve injury, diabetic neuropathy, and neurodegenerative disease. The science behind NGF is genuinely compelling, but its real-world clinical applications remain condition-specific, and patients should be cautious of any provider offering NGF therapy as a broad, one-size-fits-all nerve regeneration solution.

The most important step for anyone considering NGF-based treatment is an accurate diagnosis and an honest conversation with a qualified specialist about what the current evidence actually supports for their specific condition — not a generalized promise of nerve regeneration.